Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @akesselheim
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @akesselheim
-
Aaron Kesselheim proslijedio/la je Tweet
A Viewpoint by
@Dr_R_Kurzrock,@DrHKantarjian,@akesselheim &@Esigal on 'New drug approvals in oncology' is now live online: https://www.nature.com/articles/s41571-019-0313-2?utm_source=twitter&utm_medium=social&utm_content=organic&utm_campaign=NRRJ_2_SJB_nrclinonc_editorial_socialposts …#caxtx#hpeoncpic.twitter.com/X0ynz4OnE9
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
6.
@JonathanDarrow published essay describing why the GAIN Act of 2012 was not working to promote development of more important new antibiotics in Open Forum Infectious Diseaseshttps://academic.oup.com/ofid/article/7/1/ofaa001/5716891 …Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
5. Ameet Sarpatwari dug into the history of the NIH Reasonable Pricing Clause, finding that there is no evidence that it suppressed government-industry commercialization of discoveries in
@AnnalsofIM https://annals.org/aim/article-abstract/2759788 …Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
4. In a project led out of
@Yale_CRIT,@cmorten2 reviewed implications of recent Supreme Court decision in Merck v Albrecht on failure-to-warn drug litigation in@ASLMENews flagship journalhttps://journals.sagepub.com/doi/abs/10.1177/1073110519897793?journalCode=lmec …Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
3.
@JonathanDarrow led description of changes in drug regulation and comprehensive review of trends in testing and FDA approval statistics over last 35 years in@JAMA_current Special Communicationhttps://jamanetwork.com/journals/jama/article-abstract/2758605 …Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
2.
@oncology_bg compared response rates (RRs) and durations of response (DORs) for cancer drugs from early trials to RCTs showing no change in RRs but higher DORs in non-RCTs -- so be careful approving drugs based on non-RCT durable response data alonehttps://jnccn.org/view/journals/jnccn/18/1/article-p36.xml …Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Busy January at
@PORTAL_Research so let me catch you up on some highlights: 1. Emily Jung et al reviewed 25 highest priced drugs in 2017 Medicare, finding 41% of active ingredients were approved by FDA in other forms going back many decades:@JournalGIMhttps://link.springer.com/article/10.1007/s11606-019-05565-8 …Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Hey look it’s Andy Reid with a hurry-up 4th quarter super bowl offense...
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
In this article, we predict when we could see generics of current brand name drugs if this policy was in place: https://journals.sagepub.com/doi/abs/10.1177/1073110519840499 …https://twitter.com/SarahKarlin/status/1221859449679372299 …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
And public sector support of new drugs:https://www.bmj.com/content/367/bmj.l5766.long …
Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Great drug pricing proposals from
@MikeBloomberg — see articles from@PORTAL_Research on one-Drug-one-patent for ex: https://www.clinicalkey.com/#!/content/playContent/1-s2.0-S1098301518321545?returnurl=https:%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS1098301518321545%3Fshowall%3Dtrue&referrer=https:%2F%2Fwww.ncbi.nlm.nih.gov%2F …https://twitter.com/MikeBloomberg/status/1221873040394539009 …
0:17Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Aaron Kesselheim proslijedio/la je Tweet
Tired: getting your study cited by other authors Wired: getting your study findings satirized by GomerBloghttps://twitter.com/GomerBlog/status/1217594104885977089 …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Here’s the original article published last year (!) in
@JAMA_currenthttps://jamanetwork.com/journals/jama/fullarticle/2697695 …Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
In depth reporting on combination drug prices featuring ex-
@PORTAL_Research fellow @ChanaSacks and one of her many fellowship projects! Anyone interested in a fellowship? Application details on our website!https://www.nbcnews.com/health/health-care/are-you-kidding-me-check-out-price-tags-combination-drugs-n1049276 …Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
See below if you have relevant work you want to submit!https://twitter.com/professorsmith/status/1208016807401021440 …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Aaron Kesselheim proslijedio/la je Tweet
Join us tomorrow! A conversation with
@RepLizMiranda and@meganranney. 12:30P, amphitheater at the Harvard School of Dental Med (188 Longwood Ave)#ThisIsOurLane cc@PORTAL_Research@HMSbioethics@MGH_GVPC@peter_masiakos@RobbieForChange@_millerjon@ThisIsOurLane@MFOLBostonpic.twitter.com/3zR5Wg6lHW
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Check out our
@HarvardOnline course on@US_FDA and US prescription drug market: "Prescription Drug Regulation, Cost and Access: Current Controversies in Context." Totally free! Quizzes and activities! Special guests! Over 12,000 enrollees to date:https://www.edx.org/course/prescription-drug-regulation-cost-and-access-curre …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Knives Out: Great movie and fun to have so many pharmaceutical policy issues tied into the plot
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Aaron Kesselheim proslijedio/la je TweetHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
Aaron Kesselheim proslijedio/la je Tweet
Thank you to our presenters Dr. Steven Lemery from FDA, Dr. Deborah Scheag from Dana-Farber, and Dr. Lisa McShane from NCI for their great talk on the challenges of precision medicine in oncology!
#policyethx#HarvardHealthPrikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.